Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.

about

Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.

Item

http://www.wikidata.org/entity/Q38614756

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Therapeutic decision-making in ...... hypomethylating agent therapy.

@en

type

Item

label

Therapeutic decision-making in ...... hypomethylating agent therapy.

@en

prefLabel

Therapeutic decision-making in ...... hypomethylating agent therapy.

@en

P1476

Therapeutic decision-making in ...... hypomethylating agent therapy.

@en

P2093

Hematology Association of South-East Korea (HASEK) study group

http://www.w3.org/2001/XMLSchema#string

Ho-Jin Shin

http://www.w3.org/2001/XMLSchema#string

Ho-Seop Lee

http://www.w3.org/2001/XMLSchema#string

Joo-Seop Chung

http://www.w3.org/2001/XMLSchema#string

Sang-Bo Oh

http://www.w3.org/2001/XMLSchema#string

Su-Hee Cho

http://www.w3.org/2001/XMLSchema#string

Sung-Nam Lim

http://www.w3.org/2001/XMLSchema#string

Sung-Woo Park

http://www.w3.org/2001/XMLSchema#string

Won-Sik Lee

http://www.w3.org/2001/XMLSchema#string

Yoon-Suk Choi

http://www.w3.org/2001/XMLSchema#string

P2860

Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia.

Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.

A network meta-analysis of randomized controlled trials of induction treatments in acute myeloid leukemia in the elderly.

Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group

Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients

Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia.

Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Acute myeloid leukemia in the real world: why population-based registries are needed.

Adult acute myeloid leukemia.

P31

scholarly article

P356

10.1007/S00277-017-3104-9

http://www.w3.org/2001/XMLSchema#string

P577

2017-08-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28828639

http://www.w3.org/2001/XMLSchema#string